Brian Elsbernd - Feb 15, 2023 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role: Chief Compliance/Legal Officer
Signature: /s/ Brian Elsbernd
Stock symbol: CPRX
Transactions as of: Feb 15, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/17/2023, 04:04 PM
Previous filing: Dec 29, 2022
Next filing: Mar 22, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CPRX	Common Stock, par value $0.001 per share	Options Exercise		+9.67K	+7.39%		140K	Feb 15, 2023	Direct	F1
transaction	CPRX	Common Stock, par value $0.001 per share	Tax liability		-2.35K	-1.68%		138K	Feb 15, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CPRX	Restricted Stock Units	Options Exercise	$0	-9.67K	-1.05%	$0.00	910K	Feb 15, 2023	Common Stock	9.67K		Direct	F1, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2	Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units.
F3	Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025.
F4	Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on February 15, 2023.